BASEL LIFE 2019

9–12 September 2019

Congress Center Basel
Switzerland

Advances in 3R

Date

Tuesday, 10 September 2019

Chairs

Prof. Laura Suter-Dick (FHNW, Switzerland)
Dr. Chantra Eskes (3RCC, Switzerland)

Abstract

The principles of 3Rs will celebrate their 60 years old in 2019. They were originally proposed in the book “The principles of humane experimental technique”, published in 1959 by Russell and Burch. The concept of the three Rs addresses the Replacement, Reduction and Refinement of animal experimentation. Fortunately, we have come a long way in 60 years. Nowadays, many scientific and technological advances facilitate the use of alternative methods in research. Also, scientific knowledge can lead to improved design of animal studies, which can potentially reduce the numbers of used animal and the severity of the interventions (animal suffering). Moreover, specific bodies, like the 3RCC (Swiss 3R competence centre: swiss3rcc.org) strongly promote education, research, dissemination and application of 3Rs. In this session, we will focus on the current status and applications of the 3R-principles in industrial and academic research. We will address the uses of alternatives to animal experimentation in drug discovery research for pharmacological and toxicological characterization of potential drugs. The session will also touch upon the relevance of animal experimentation for the detection of human-relevant effects.

Tuesday, 10 September 2019

10.00 - 13.00

10.00
Introduction
Dr. Chantra Eskes (3RCC, CH)

10.10
Making better use of non-animal approaches in science
Dr. Maurice Whelan (European Commission Joint Research Centre (JRC), Ispra, IT)

10.35
iPSC-derived BrainSpheres: 21th century tools for human brain disease modelling and neurotoxicology testing
Dr. David Pamies (University of Lausanne, Lausanne, CH)

11.00
Break

11.30
Non-clinical models to predict toxicities of immunotherapies in patients
Dr. Ekaterina Breous-Nystrom (F. Hoffmann-La Roche, Basel, CH)

11.55
Culture of Care in an industrial setting
Dr. Thomas Bertelsen (Novo Nordisk, Malov, DK)

12.20
Concluding remarks

Prof. Laura Suter-Dick (FHNW), Basel, CH)

13.00
Lunch Break & Industry Symposia

Room Osaka